Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. The company was incorporated in 2009 and is based in Huddinge, Sweden.
Metrics to compare | SPRINT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSPRINTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.1x | −2.9x | −0.6x | |
PEG Ratio | 0.50 | −0.07 | 0.00 | |
Price/Book | 25.7x | 5.5x | 2.6x | |
Price / LTM Sales | 3.1x | 5.2x | 3.4x | |
Upside (Analyst Target) | 69.5% | 84.9% | 42.0% | |
Fair Value Upside | Unlock | 0.0% | 5.0% | Unlock |